Drug Profile
Solifenacin/tamsulosin - Astellas Pharma
Alternative Names: EC905; Solifenacin succinate/tamsulosin hydrochloride; Tamsulosin hydrochloride/solifenacin succinate; Tamsulosin/solifenacin; Urizia; Vesomni; VolutsaLatest Information Update: 14 Feb 2019
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; Rovi
- Class Amines; Antispasmodics; Benzene derivatives; Esters; Ethers; Isoquinolines; Quinuclidines; Small molecules; Sulfonamides; Urologics
- Mechanism of Action Alpha-1a adrenergic receptor antagonists; Cholinergic receptor antagonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Benign prostatic hyperplasia
Most Recent Events
- 14 Feb 2019 Chemical structure information added
- 30 Apr 2015 No recent reports on development identified - Phase-III for Benign prostatic hyperplasia in Austria, Belarus, Belgium, France, Germany, Hungary, Italy, Poland, Russia and Slovakia (PO)
- 11 Feb 2015 Rovi acquires the marketing rights of solifenacin/tamsulosin in Spain